InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Thursday, 10/03/2019 12:00:21 PM

Thursday, October 03, 2019 12:00:21 PM

Post# of 561
News: $CBIO Catalyst Biosciences Provides DalcA Phase 2b Trial Update

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for...

Read the whole news CBIO - Catalyst Biosciences Provides DalcA Phase 2b Trial Update
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CBIO News